Checking the Hippo in Sarcomatoid Renal Cell Carcinoma with Immunotherapy

Cancer shared this article with you from Inoreader Checking the Hippo in Sarcomatoid Renal Cell Carcinoma with Immunotherapy Via Clinical Cancer Research recent ... Subset analysis of patients with sarcomatoid renal cell carcinoma (sRCC) included in the CheckMate 214 trial of ipilimumab-nivolumab versus sunitinib showed improved outcomes in sRCC with ipilimumab-nivolumab. The use of checkpoint inhibitor–based regimens in sRCC, for which therapeutic options were once limited, is further supported by additional clinical trials. See related article by Tannir et al., p. 78 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.